Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma.

Ping, Nana; Qu, Changju; Li, Mengyun; Kang, Liqing; Kong, Danqin; Chen, Xiaochen; Wu, Qian; Xia, Fan; Yu, Lei; Yao, Hong; Yan, Lingzhi; Wu, Depei; Jin, Zhengming

Ping, Nana; Qu, Changju; Li, Mengyun; Kang, Liqing; Kong, Danqin; Chen, Xiaochen; Wu, Qian; Xia, Fan; Yu, Lei; Yao, Hong; Yan, Lingzhi; Wu, Depei; Jin, Zhengming.

Afiliação

Ping N; Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.
Qu C; Institute of Blood and Marrow Transplantation, Suzhou, China.
Li M; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Kang L; Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.
Kong D; Institute of Blood and Marrow Transplantation, Suzhou, China.
Chen X; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Wu Q; Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.
Xia F; Institute of Blood and Marrow Transplantation, Suzhou, China.
Yu L; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
Yao H; Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, China.
Yan L; School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, China.
Wu D; Department of Hematology, the First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.
Jin Z; Institute of Blood and Marrow Transplantation, Suzhou, China.